Western Blot (WB)
(Western Blot Positive WB detected in: 293T whole cell lysate, Hela whole cell lysate, L02 whole cell lysate, PC-3 whole cell lysate, A549 whole cell lysate All lanes: MET antibody at 1:1500 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 156, 158, 86 kDa Observed band size: 156 kDa)
MET recombinant antibody
MET Antibody
IHC: 1:50-1:200
IF: 1:20-1:200
FC/FACS: 1:20-1:200
Western Blot (WB)
(Western Blot Positive WB detected in: 293T whole cell lysate, Hela whole cell lysate, L02 whole cell lysate, PC-3 whole cell lysate, A549 whole cell lysate All lanes: MET antibody at 1:1500 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 156, 158, 86 kDa Observed band size: 156 kDa)
Western Blot (WB)
(Western Blot Positive WB detected in: 293T whole cell lysate, Hela whole cell lysate, L02 whole cell lysate, PC-3 whole cell lysate, A549 whole cell lysate All lanes: MET antibody at 1:1500 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 156, 158, 86 kDa Observed band size: 156 kDa)
Immunohistochemistry (IHC)
(IHC image diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4 degree C overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.)
Immunohistochemistry (IHC)
(IHC image diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4 degree C overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.)
Immunohistochemistry (IHC)
(IHC image diluted at 1:100 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4 degree C overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.)
Immunohistochemistry (IHC)
(IHC image diluted at 1:100 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4 degree C overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.)
Immunofluorescence (IF)
(Immunofluorescence staining of Hela Cells at 1?50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4 degree C. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG ?H+L?.)
Immunofluorescence (IF)
(Immunofluorescence staining of Hela Cells at 1?50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4 degree C. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG ?H+L?.)
Flow Cytometry (FC/FACS)
(Overlay histogram showing Hela cells stained with (red line) at 1?50. The cells were incubated in 10% normal goat serum to block non-specific protein-protein interactions followedby the antibody (1ug/1*106cells) for 1 h at 4?.The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 30min at 4?. Control antibody (green line) was Rabbit IgG (1ug/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.)
Flow Cytometry (FC/FACS)
(Overlay histogram showing Hela cells stained with (red line) at 1?50. The cells were incubated in 10% normal goat serum to block non-specific protein-protein interactions followedby the antibody (1ug/1*106cells) for 1 h at 4?.The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 30min at 4?. Control antibody (green line) was Rabbit IgG (1ug/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.)
NCBI and Uniprot Product Information
NCBI Description
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Uniprot Description
Function: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. Ref.14 Ref.17 Ref.25Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells. Ref.14 Ref.17 Ref.25
Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
Enzyme regulation: In its inactive state, the C-terminal tail interacts with the catalytic domain and inhibits the kinase activity. Upon ligand binding, the C-terminal tail is displaced and becomes phosphorylated, thus increasing the kinase activity.
Subunit structure: Heterodimer made of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1. Interacts when phosphorylated with downstream effectors including STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1. Interacts with SPSB1, SPSB2 and SPSB4
By similarity. Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction. Interacts with MUC20; prevents interaction with GRB2 and suppresses hepatocyte growth factor-induced cell proliferation. Interacts with GRB10. Ref.12 Ref.16 Ref.18 Ref.19 Ref.20 Ref.22 Ref.24 Ref.25 Ref.26 Ref.34 Ref.48
Subcellular location: Membrane; Single-pass type I membrane protein. Isoform 3: Secreted.
Tissue specificity: Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain. Ref.11 Ref.13
Domain: The kinase domain is involved in SPSB1 binding.The beta-propeller Sema domain mediates binding to HGF.
Post-translational modification: Autophosphorylated in response to ligand binding on Tyr-1234 and Tyr-1235 in the kinase domain leading to further phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site. Ref.15 Ref.16 Ref.23 Ref.26Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Ref.15 Ref.16 Ref.23 Ref.26Ubiquitinated. Ubiquitination by CBL regulates the receptor stability and activity through proteasomal degradation. Ref.21
Involvement in disease: Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.Defects in MET may be associated with gastric cancer.Hepatocellular carcinoma (HCC) [MIM:114550]: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.43Renal cell carcinoma papillary (RCCP) [MIM:605074]: A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.41 Ref.42 Ref.44 Ref.45A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies. Ref.51
Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family.Contains 3 IPT/TIG domains.Contains 1 protein kinase domain.Contains 1 Sema domain.
Research Articles on MET
Similar Products
Product Notes
The MET met (Catalog #AAA7136846) is a Recombinant Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The MET Antibody reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's MET can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FC/FACS). WB: 1:500-1:5000 IHC: 1:50-1:200 IF: 1:20-1:200 FC/FACS: 1:20-1:200. Researchers should empirically determine the suitability of the MET met for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "MET, Monoclonal Recombinant Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
